Vireo Growth (VREOF) Cost of Revenue (2020 - 2026)
Vireo Growth's (VREOF) quarterly Cost of Revenue came in at $46.9 million in Q1 2026, up 287.6% year-on-year from $12.1 million in Q1 2025, and down 1.53% quarter-over-quarter from $47.6 million in Q4 2025.
Vireo Growth (VREOF) Cost of Revenue (2020 - 2026) Analysis & Trends
Vireo Growth has disclosed Cost of Revenue across 7 years of filings, most recently posting $46.9 million for Q1 2026.
- Cost of Revenue for Q1 2026 came in at $46.9 million, up 287.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $176.4 million (up 608.58% YoY), and the FY2025 annual result was $141.7 million, up 191.43% from the prior year.
- Cost of Revenue came in at $46.9 million for Q1 2026 at Vireo Growth, down from $47.6 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $54.3 million in Q3 2025 to a low of $161782.0 in Q3 2023.
- The 5-year median for Cost of Revenue is $240322.0 (2022), against an average of $12.0 million.
- Across the five-year window, Cost of Revenue slumped 96.3% in 2022 and jumped 22519.81% in 2025, its largest moves.
- Vireo Growth's Cost of Revenue stood at $240322.0 in 2022, then declined by 25.93% to $178017.0 in 2023, then soared by 6849.53% to $12.4 million in 2024, then jumped by 284.99% to $47.6 million in 2025, then dropped by 1.53% to $46.9 million in 2026.
- The last three Cost of Revenue figures came in at $46.9 million (Q1 2026), $47.6 million (Q4 2025), and $54.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 696.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | 641.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 133.40 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 34.44 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 13.80 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | 586.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 155.56 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 52.68 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 222.00 Mn |
| 10 | Vireo Growth | - | - | 59.30 Mn | 46.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.90 Mn |
| Mar 31, 2026 | 46.90 Mn |
| Dec 31, 2025 | 47.63 Mn |
| Dec 31, 2025 | 47.63 Mn |
| Sep 30, 2025 | 54.27 Mn |
| Sep 30, 2025 | 54.27 Mn |
| Jun 30, 2025 | 27.65 Mn |
| Jun 30, 2025 | 27.65 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Dec 31, 2024 | 12.37 Mn |
| Dec 31, 2024 | 12.37 Mn |
| Sep 30, 2024 | 239,932.00 |
| Sep 30, 2024 | 239,932.00 |
| Jun 30, 2024 | 189,946.00 |
| Jun 30, 2024 | 189,946.00 |
| Mar 31, 2024 | 222,014.00 |
| Mar 31, 2024 | 222,014.00 |
| Dec 31, 2023 | 178,017.00 |
| Dec 31, 2023 | 178,017.00 |